SureGene™ is a powerful method for improving response rates to antipsychotic drugs and reducing hospitalizations, adverse events, and treatment costs. Our antipsychotic efficacy markers have effect sizes nearly twice the size of the most effective drug on the market.1
For drug-naïve patients or patients who are not currently on medication
Poor efficacy, tolerability, or patient satisfaction with existing medications
Exacerbations of psychosis, especially those that lead to hospitalization
The SureGene™ test report provides actionable information regarding the implications of the SureGene™ genetic test on drug response propensities, specifically including:
The SureGene™ report, and much more, is available through the SureGene™ Portal.
As with any laboratory test, SureGene™ should not be used as the sole means of treatment decision making, and should be regarded by the ordering physician as adjunctive to the overall patient management strategy. Genotyping results do not eliminate the necessity to account for non-genetic factors that can influence dose requirements for, or responses to, medications that are metabolized by these enzyme systems. Drug-drug interactions that lead to enzymatic inhibition or induction may lead to altered metabolism. Results should always be interpreted in context with the comprehensive clinical picture and all co-administered medications.